Its upregulation in various cancers and association with prognosis suggests that cancers may exploit this pathway for immune evasion as in the case of other T cell co-inhibitory molecules such as CTLA-4 and PD-1 (34, 35). This evidence concerns the gene PDCD1 and cancer.